It was a huge pleasure to catch up with our esteemed Editorial Board member, Cynthia Matossian (Matossian Eye Associates, Hopewell and Hamilton, NJ, USA), as she talked us through her AAO presentation on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.
Questions
- What is the rationale for the use of dexamethasone intraocular suspension 9% at the conclusion of cataract surgery? (00:16)
- What were the aims and design of the study you presented at AAO? (01:50)
- What did the findings of the study teach us about the use of dexamethasone intraocular suspension 9%? (03:16)
- How are these findings likely to impact on future clinical practice? (04:06)
- Which patients are likely to benefit most from this treatment approach? (05:55)
Speaker Disclosure: Dr Cynthia Matossian is a consultant to EyePoint.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of AAO 2020.
